{
  "nctrialId": "HC-1808",
  "title": "A Randomized Open-Label, Placebo-Controlled  Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Major Depressive Disorder",
  "officialTitle": "A Randomized Open-Label, Placebo-Controlled  Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Major Depressive Disorder",
  "sponsor": "Sunnybrook Research Institute",
  "indication": "Major Depressive Disorder",
  "phase": "Phase 4",
  "fileName": "HC-1808.json",
  "fileSize": 176190,
  "date": "2024-01-28",
  "completionDate": "2027-12-09",
  "drugName": "PSO-602 (phosphodiesterase-4 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a randomized open-label, placebo-controlled  study designed to evaluate the efficacy and safety of PSO-602 (phosphodiesterase-4 inhibitor) in patients with Major Depressive Disorder. The study will enroll approximately 374 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-82 years\n- Confirmed diagnosis of Major Depressive Disorder\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}